Korea University Medicine study highlights a new biomarker for major depressive disorder

In appearance, the human brain’s outermost layer, called the cortex, is a maze of tissue folds. The peaks or raised surfaces of these folds, called gyri, play an important role in the proper functioning of the brain. Improper gyrification—or the development of gyri—has been implicated in various neurological disorders, one of them being the debilitating and widespread mental illness­, major depressive disorder (MDD). Although prior studies have shown that abnormal cortical folding patterns are associated with MDD, a reliable indicator has so far remained out of reach.

Now, in a positive turn of events, researchers led by Professor Byung-Joo Ham and Associate Professor Kyu-Man Han from Korea University Medicine have reported the successful identification of a neuroimaging-based biomarker for MDD in a recent study published on 8 May 2023 in Psychological Medicine. Talking about the unique finding that sets apart their study from the previous ones, Prof. Ham explains, “Our first-of-its-kind study investigated the association of MDD with the local gyrification index or LGI of multiple cortical regions at the whole-brain level and the association of LGI with the clinical characteristics of MDD.”

But what indeed is local gyrification index (LGI)?

LGI is a measurement of cortical folding that is derived from brain scans as a ratio of the curved and smoothed surfaces of the cortex in a region of interest. In this study, the researchers compared the LGI values from multiple cortical regions in the brain of patients with MDD with those of healthy individuals. The neuroimaging data used to compare and analyze both groups were obtained from magnetic resonance imaging scans.

Prof. Ham and his team showed that LGI values from multiple cortical regions in the brain of patients with MDD showed hypogyrification—a condition characterized by decreased cortical folding—when compared with healthy individuals. They found that patients with MDD showed significantly lower LGI values in 7 out of the 66 cortical regions assessed (in both hemispheres of the brain), which included the prefrontal cortex, anterior cingulate cortex, insula, and several temporal and parietal regions. Notably, the most significant hypogyrification was observed in the left pars triangularis of patients with MDD. These findings are nothing short of a breakthrough in MDD research!

When asked to share his thoughts about the study’s results, Dr. Han asserts that there is more to their findings than what meets the eye. “The cortical regions that we assessed in our study have been previously shown to affect emotional regulation. This means that abnormal cortical folding patterns may be associated with the dysfunction of neural circuits involved in emotional regulation, thus contributing to the pathophysiology of MDD,” he adds reflectively.  

The study’s findings firmly establish LGI as a relatively stable neuroimaging marker for MDD, when compared with previously identified biomarkers. This is because LGI values reflect the long-drawn developmental process of gyrification that is not spontaneously affected by an individuals’ state during the measurement process. It is also worth highlighting the robustness of this study, given that it involved a larger sample size of participants, which gives it an edge over similar studies conducted previously.

Interestingly, the researchers noted that the clinical characteristics of MDD, including the recurrence and duration of illness in patients, were associated with increased gyrification in several occipital and temporal cortical regions. However, they did not observe any significant difference in the LGI values in these regions between the patient and control groups.

With the head start given by this study, future research could explore the genetic factors that predispose individuals to abnormal cortical folding patterns, and, in turn, MDD. The study can also serve as a roadmap for the selection of cortical regions as targets for medical treatments aimed at reducing the symptoms of this condition.

Overall, by identifying a new biomarker for MDD, this study has paved the way for a deeper understanding of a serious and pervasive mental health problem, which could hopefully take the medical community one step closer to finding an effective solution in the future.

***

Reference

DOI: https://doi.org/10.1017/s0033291723001216  

About the Korea University Medicine

Korea University (KU), located in Seoul, South Korea, is a leading university established in 1905, renowned for its academic excellence and contributions to higher education. Within KU, Korea University Medicine (KU Medicine) is a top-ranked medical institution, comprising campuses like Anam Hospital, Guro Hospital, Ansan Hospital, Cheongdam Goyeong Campus, and Jeongneung Mediscience Park. KU Medicine also has educational institutions affiliated to it, including the College of Medicine, Graduate School of Public Health, and Graduate School of Clinical Dentistry, driving remarkable advancements in medical treatment, education, research, and social contributions.

Website: https://www.kumc.or.kr/en/index.do

About Professor Byung Joo Ham

Prof. Byung-Joo Ham is a Professor in the Department of Psychiatry at Korea University Medicine, the Head of the Department of Psychiatry, and the Director of Human Behavior and Gene Research Center at Korea University Medicine. As a former Vice President of research at Korea University, he has led multiple projects since 2005. He has published nearly 140 papers on biomarkers related to major depressive disorder (MDD). He has also developed the world’s first neuroimaging marker for the diagnosis of MDD and facilitated its commercialization.  

ORCID: https://orcid.org/0000-0002-0108-2058

About Associate Professor Kyu-Man Han

Dr. Kyu-Man Han works as an Associate Professor of Psychiatry at Korea University Medicine and as a practicing psychiatrist at Korea University Anam Hospital. He has authored nearly 90 publications in the field of mental health. His work focusses on developing biomarkers for depression, digital cognitive behavior therapy, and the social determinants of mental health. 

ORCID: https://orcid.org/0000-0002-1982-4216